FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol

FDA approves new kind of cholesterol pill

The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, offering a once-daily tablet alternative to injectable therapies for adults with high cholesterol. This breakthrough provides a new option for patients needing further LDL-C reduction despite existing treatments, marking a significant step forward in managing cardiovascular disease risks.

"Cardiovascular disease remains the leading cause of death in the United States, and elevated LDL cholesterol is one of its most important modifiable risk factors."